May 18, 2021 When omecamtiv mecarbil is used in patients who have chronic heart failure with reduced ejection fraction (HFrEF), the greater beneficial impact on clinical outcomes is seen in those with lower ejection fractions, a secondary analysis of the placebo-controlled GALACTIC-HF trial shows. Among the prespecified subgroups in the trial, LVEF was the strongest modifier of the treatment effect, with larger reductions in the risk of HF events or CV death observed as values fell ( P = 0.004 for interaction). Reductions in NT-proBNP were greater at the lower end of the range, as well, John Teerlink, MD (San Francisco VA Medical Center and the University of California, San Francisco), reported during the recent virtual American College of Cardiology (ACC) 2021 Scientific Session.